Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient
This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
Small Cell Carcinoma, Hypercalcaemic Type|Ovarian Cancer
DRUG: Pembrolizumab
Progression free survival, Determined by CT scans, 2 years
overall performance status, Eastern cooperative oncology group (ECOG) score, patient-reported symptoms as well as objective measurements by CT scans., 2 years|Objective evidence of response to treatment, Recorded with CA-125 every 6 weeks and CT scans after every 2 cycles of treatment, 2 years|Exploratory Endpoint, Exploratory Endpoint will be measured by circulating DNA to monitor minimal residual disease, 2 Years
It is an open-label single patient Clinical Trial to be conducted at Princess Margaret Cancer Centre for a patient with Small Cell Carcinoma of Ovary - Hypercalcemic Type (SCCOHT) who has rare and aggressive malignancy with no current consensus on treatment approach and surveillance.